The treatment of systemic sclerosis (SSc) represents a great clinical challenge because of the complex disease pathogenesis including vascular, fibrotic, and immune T- and B-lymphocyte-mediated alterations. Therefore, SSc should be treated by combined or sequential therapies according to prevalent clinico-pathogenetic phenotypes. Some preliminary data suggest that rituximab (RTX) may downregulate the B-cell over expression and correlated immunological abnormalities.
Rituximab in the treatment of patients with systemic sclerosis. Our experience and review of the literature
COLACI, Michele
2015-01-01
Abstract
The treatment of systemic sclerosis (SSc) represents a great clinical challenge because of the complex disease pathogenesis including vascular, fibrotic, and immune T- and B-lymphocyte-mediated alterations. Therefore, SSc should be treated by combined or sequential therapies according to prevalent clinico-pathogenetic phenotypes. Some preliminary data suggest that rituximab (RTX) may downregulate the B-cell over expression and correlated immunological abnormalities.File in questo prodotto:
File | Dimensione | Formato | |
---|---|---|---|
Rituximab in the treatment of patients with systemic sclerosis.pdf
accesso aperto
Tipologia:
Versione Editoriale (PDF)
Dimensione
315.08 kB
Formato
Adobe PDF
|
315.08 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.